Europe clamps down on prices of orphan drugs

04/8/2013 | Bloomberg

Cash-strapped European governments have been balking at high prices for drugs to treat rare diseases, sometimes winning significant price concessions from manufacturers. Payers in the U.S. are likely to follow suit, says Mary Dunkle, a vice president at patient advocacy group National Organization for Rare Disorders. Thirteen European Union members are considering a plan to collaborate on cost-benefit analyses of orphan drugs, which might increase access across Europe, says Richard Bergstrom, director general of the European Federation of Pharmaceutical Industries and Associations.

View Full Article in:

Bloomberg

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ